| Literature DB >> 28800599 |
Yoon Seob Kim1, Dukyong Yoon1,2, JungHyun Byun1, Hojun Park1, Ahram Lee1, Il Hyun Kim1, Sukhoon Lee3, Hong-Seok Lim4, Rae Woong Park1,2.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2017 PMID: 28800599 PMCID: PMC5553787 DOI: 10.1371/journal.pone.0182889
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Vessel and stent terms used in PCI reports and their categories in this study.
| Vessel/stent categories | Vessel/stent terms used in PCI reports | |||
|---|---|---|---|---|
| Vesssel | LAD | LAD, Di, D1, D2, diagonal/Dx | ||
| LCx | LCx, OM, RI/Ramus | |||
| LM | LM, LM-LAD, LM-LCx | |||
| RCA | RCA, PDA, PLV, PLB | |||
| Stent | BMS | Vision, Genoss, Coroflex Blue, Zeta | ||
| DES | First generation | Cypher, Coroflex Please, Taxus | ||
| Second generation | Durable polymer | Resolute family, Promus family, Xience family, Endeavor | ||
| Biodegradable polymer | Biomatrix, Desyne, Nobori, Orsiro |
LAD, left anterior descending artery; LCx, left circumflex; LM, left main; RCA, right coronary artery; BMS, bare metal stent; DES, drug-eluting stent; D1, the first diagonal artery; D2, the second diagonal artery; Dx, diagonal artery; OM, obtuse marginal; PDA, posterior descending artery; PLV, posterior left ventricular branch; PLB, posterior lateral branch.
Fig 1The percutaneous coronary intervention (PCI)-related parameter information extraction process from free-text PCI procedure reports.
Mean sensitivities, specificities, and F-measures for each iterative round.
| Round | Mean Sensitivity | Mean Specificity | Mean F-measure |
|---|---|---|---|
| Primary | 0.741 | 0.999 | 0.864 |
| Secondary | 0.960 | 1.000 | 0.959 |
| Tertiary | 0.991 | 1.000 | 0.991 |
Baseline, procedural, and outcome findings.
| Variable | All | DP-DES | BP-DES | |
|---|---|---|---|---|
| No. of patients, n | 3817 | 2468 | 568 | - |
| Age, mean ± SD | 62.75 ± 11.77 | 62.19 ± 11.80 | 63.14 ± 11.61 | 0.080 |
| Male, n (%) | 2724 (71%) | 1799 (73%) | 386 (68%) | 0.021 |
| Hypertension, n (%) | 1756 (46%) | 1126 (46%) | 263 (46%) | 0.806 |
| Diabetes mellitus, n (%) | 746 (20%) | 489 (20%) | 116 (20%) | 0.788 |
| Average duration of DAPT (days), mean ± SD | 572.59 ± 444.77 | 559.29 ± 425.71 | 549.12 ± 384.32 | 0.578 |
| Duration of DAPT over 12 months, n (%) | 2326 (61%) | 1510 (61%) | 347 (61%) | 1.000 |
| No. of treated vessels, n (%) | ||||
| LAD | 2565 (67%) | 1474 (60%) | 349 (61%) | 0.480 |
| RCA | 1346 (35%) | 806 (33%) | 156 (27%) | 0.019 |
| LCx | 1288 (34%) | 639 (26%) | 145 (26%) | 0.900 |
| LM | 413 (11%) | 312 (13%) | 37 (7%) | < 0.001 |
| Average diameter of stents per target vessel (mm), mean ± SD | 2.61 ± 1.19 | 3.11 ± 1.19 | 3.07 ± 1.19 | 0.020 |
| Total length of stents per target vessel (mm), mean ± SD | 27.56 ± 19.24 | 34.17 ± 19.24 | 28.64 ± 19.24 | < 0.001 |
| No. of stents per target vessel, mean ± SD | 1.06 ± 0.65 | 1.28 ± 0.65 | 1.23 ± 0.65 | 0.029 |
| Post-stent non-compliant balloon use, n (%) | 1970 (52%) | 1335 (54%) | 293 (52%) | 0.301 |
| Procedures with femoral artery approach, n (%) | 3087 (81%) | 1998 (81%) | 450 (79%) | 0.378 |
| Vessels treated by major stent types, n (%) | ||||
| Xience family | 995 (40%) | |||
| Promus family | 1143 (46%) | |||
| Resolute family | 978 (40%) | |||
| Endeavor | 162 (7%) | |||
| Nobori | 482 (85%) | |||
| Biomatrix | 185 (33%) | |||
| Orsiro | 22 (4%) | |||
| Outcomes | ||||
| Cases of TVR, n (%) | 222 (5.8%) | 97 (3.9%) | 18 (3.2%) | 0.462 |
| Observation period, days | 730.31 ± 463.78 | 693.98 ± 463.78 | 724.12 ± 463.78 | 0.098 |
SD, standard deviation; DP-DES, durable polymer drug eluting stents; BP-DES, biodegradable polymer drug eluting stents; DAPT, dual antiplatelet therapy; LAD, left anterior descending artery; RCA, right coronary artery; LCx, left circumflex; LM, left main; TVR, target vessel revascularization.
*DP-DES group and BP-DES group were compared by Pearson’s chi-squared test for categorical variables and by Student’s t-test for continuous variables
Fig 2Comparison of target vessel revascularization free survival between the first- and second-generation stents.
Hazard ratios of first- versus second-generation stents and the observed variables in PCI patients.
| Variable | HR (95% CI) | |
|---|---|---|
| Second-generation stents (reference, first-generation stents) | 0.423 (0.284–0.630) | < 0.001 |
| Age | 0.978 (0.962–0.994) | 0.009 |
| Sex (male) | 1.010 (0.652–1.564) | 0.966 |
| Hypertension | 3.469 (2.294–5.245) | < 0.001 |
| Diabetes mellitus | 2.100 (1.420–3.107) | < 0.001 |
| Total stent length | 1.005 (0.983–1.027) | 0.661 |
| Average stent diameter | 0.943 (0.571–1.556) | 0.818 |
| Non-compliant high pressure balloon use | 1.349 (0.919–1.980) | 0.126 |
| Target vessel (reference, LAD) | ||
| LCx | 0.697 (0.401–1.211) | 0.200 |
| LM | 0.415 (0.163–1.055) | 0.065 |
| RCA | 1.121 (0.732–1.716) | 0.599 |
| No. of stents used | 0.833 (0.419–1.656) | 0.601 |
| Radial artery approach | 0.714 (0.405–1.259) | 0.244 |
| Emergent PCI | 3.270 (2.025–5.280) | < 0.001 |
| DAPT over 12 months | 0.389 (0.270–0.559) | < 0.001 |
HR, hazard ratio; CI, confidence interval; LAD, left anterior descending artery; RCA, right coronary artery; LCx, left circumflex; LM, left main; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention.
Hazard ratios of DP-DES vs. BP-DES and the observed variables in PCI patients.
| Variable | HR (95% CI) | |
|---|---|---|
| Biodegradable stents (reference, durable stents) | 0.568 (0.281–1.147) | 0.114 |
| Age | 0.980 (0.961–0.999) | 0.040 |
| Sex (male) | 1.008 (0.597–1.702) | 0.975 |
| Hypertension | 5.111 (2.983–8.757) | < 0.001 |
| Diabetes mellitus | 2.195 (1.386–3.477) | 0.001 |
| Total stent length | 1.007 (0.982–1.032) | 0.588 |
| Average stent diameter | 1.031 (0.577–1.843) | 0.918 |
| Non-compliant high pressure balloon use | 1.392 (0.879–2.203) | 0.158 |
| Target vessel (reference, LAD) | ||
| LCx | 0.417 (0.196–0.887) | 0.023 |
| LM | 0.319 (0.097–1.052) | 0.061 |
| RCA | 0.967 (0.589–1.588) | 0.894 |
| No. of stents used | 0.823 (0.381–1.774) | 0.618 |
| Radial artery approach | 0.411 (0.178–0.951) | 0.038 |
| Emergent PCI | 3.861 (2.273–6.559) | < 0.001 |
| DAPT over 12 months | 0.389 (0.251–0.603) | < 0.001 |
HR, hazard ratio; CI, confidence interval; LAD, left anterior descending artery; RCA, right coronary artery; LCx, left circumflex; LM, left main; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention.
Adjusted TVR risk of each stent compared to the other second generation stents.
| Variable | Adjusted HR | |
|---|---|---|
| Xience family | 0.717 (0.392–1.312) | 0.280 |
| Promus family | 1.096 (0.691–1.740) | 0.696 |
| Resolute family | 1.145 (0.697–1.880) | 0.594 |
| Endeavor | 2.576 (1.273–5.210) | 0.008 |
| Nobori | 0.721 (0.328–1.585) | 0.416 |
| Biomatrix | 0.376 (0.091–1.552) | 0.176 |
HR, hazard ratio; CI, confidence interval.
*Adjusted for age, sex, hypertension, diabetes mellitus, total length and average diameter of stents, non-compliant high pressure balloon use, target vessel (LAD, LCx, LM, or RCA), the number of stent used, approach artery, emergent percutaneous coronary intervention, and dual antiplatelet therapy over 12 months.